Sedentary lifestyle, overweight, and age are some of the major factors contributing to growing prevalence of diabetes cases across the globe. As per a report published by the World Health Organization (WHO), in 2014, approximately 1.9 billion people were identified as overweight wherein 600 million were categorized as obese.
Growing discovery of new medication classes with the objective of stopping the steep rise in worldwide
prevalence has invigorated the growth of the diabetes drugs market. Growing body of research in
pharmacological therapies, with focus on efficacy, safety, and patient adherence, has expanded market
avenues for antidiabetic drugs.
Growing classes of drugs to treat type 2 diabetes mellitus has been a key driver and accelerator for
expansion of the diabetes drugs market. According to a projection by Transparency Market Research, the
diabetes drugs market is estimated to garner a CAGR of 3.6% from 2017 to 2025.
There is always a desperate need for new drugs that can enable patients to achieve better glycemic control
with least side effects. This will contribute the revenues to rise to worth of US$58.4 bn by 2025-end. In
coming years, pharmaceutical and biotech companies will lay more emphasis on convenience of
administration of medications and their dosing frequency.
Request Brochure of Report -
High Prevalence Makes North America Rewarding Market for Anti-diabetes Drugs Makers
Per an estimate by the International Diabetes Foundation (IDF), the prevalence of diabetes will touch 552
million by 2030. Particularly, type 2 diabetes mellitus have over the past few years has resulted in high
hospitalization costs in developed regions such as North America, with its high rate of comorbidities and
complications. The high prevalence of diabetes mellitus has driven the North America to gain dominant
share in 2016 in the diabetes drugs market. Particularly in the U.S., various treatment regimens have been
intensely researched upon, imparting momentum to the aforementioned regional market.
Type 2 Diabetes With Vast Unmet Need in Patients Bellwether for Market Growth Globally
The type 2 diabetes segment has in recent years has attracted groundswell of interest due to fact that it
has been leading cause of cardiovascular disord